BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Haduvio (Nalbuphine ER) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Haduvio (Nalbuphine ER)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07946575-10655@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Haduvio (Nalbuphine ER): Phase 1 readout est. (NCT07946575)
DESCRIPTION:Haduvio (Nalbuphine ER)\, phase 1.\nStudy: A Study of the Poten
 tial Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine 
 Extended-Release Tablets (NAL ER) in Healthy Participants\nEstimated prima
 ry completion: 30 November 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nalbuphine-er#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07946575
URL:https://assetmemo.bio/drug/nalbuphine-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868419-10655@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Haduvio (Nalbuphine ER): Phase 3 readout est. (NCT07868419)
DESCRIPTION:Haduvio (Nalbuphine ER)\, phase 3\, Chronic Cough in Idiopathic
  Pulmonary Fibrosis.\nStudy: Idiopathic Pulmonary Fibrosis (IPF)-Related C
 hronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
 \nEstimated primary completion: August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nalbuphine-er#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07868419
URL:https://assetmemo.bio/drug/nalbuphine-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671924-10655@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Haduvio (Nalbuphine ER): Phase 2 readout est. (NCT07671924)
DESCRIPTION:Haduvio (Nalbuphine ER)\, phase 2.\nStudy: The Effect of Nalbup
 hine Extended-Release (NAL ER) on Cough in Participants With Refractory Ch
 ronic Cough (RCC)\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nalbuphine-er#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07671924
URL:https://assetmemo.bio/drug/nalbuphine-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671911-10655@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Haduvio (Nalbuphine ER): Phase 3 readout est. (NCT07671911)
DESCRIPTION:Haduvio (Nalbuphine ER)\, phase 3\, Chronic Cough in Idiopathic
  Pulmonary Fibrosis.\nStudy: Idiopathic Pulmonary Fibrosis (IPF)-Related C
 hronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets\n
 Estimated primary completion: June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nalbuphine-er#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07671911
URL:https://assetmemo.bio/drug/nalbuphine-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
